Oxford Sciences Innovation, which commercialises the science and technology from the University of Oxford, is expanding at The Oxford Science Park.
Driven by its rapid rate of growth and creation of spin-out companies, OSI is taking 17,260 sq ft of office and laboratory space on the second floor of the state-of-the-art Schrödinger Building. The space will be used by three of its spin-out companies – Orbit Discovery (peptide drugs for chronic diseases), OMass Technologies (mass spectrometry of protein complexes for drug discovery) and Vaccitech (novel vaccines for flu and cancer).
“Having invested almost £100m in its portfolio companies since inception, OSI is a key player in the UK innovation network. The Oxford Science Park is delighted to strengthen its links with OSI and I have little doubt its spin-out companies will thrive and grow here,” said Piers Scrimshaw-Wright, Managing Director of The Oxford Science Park.
OSI was established in 2015 to exploit and commercialise research findings from academic departments across the University. Since then it has raised over £600m and set up over 50 companies. The company says that as the portfolio companies have grown they need extra capacity and laboratory space, and The Oxford Science Park’s Schrödinger Building is the ideal location for the next phase of their growth.